Kenvue’s SWOT analysis: consumer health stock faces headwinds

Kenvue Inc. (NYSE:KVUE), the consumer health company spun off from Johnson & Johnson, navigates a challenging operating environment marked by top-line pressures and strategic uncertainty. The company maintains its position in the consumer health products market while confronting headwinds from destocking, low disease incidence levels, and slowing retail trends that have weighed on recent performance.

Kenvue has experienced weaker-than-expected top-line performance through 2025, with analysts pointing to multiple factors constraining growth. The company faces continued destocking pressures as retailers adjust inventory levels, while low incidence levels for common ailments have reduced consumer demand for certain health products. These dynamics have created headwinds that persist despite the company’s efforts to stabilize operations following its separation from Johnson & Johnson.

The company’s 2025 guidance reflects these challenges, with management projecting low single-digit percentage declines in revenue and an 8.5 to 12.5 percent drop in earnings per share for the fiscal year. This outlook demonstrates the magnitude of pressures facing the business, though the company has maintained this guidance despite ongoing macroeconomic uncertainties.

Analysts note that retail trends have shown signs of slowing, adding another layer of complexity to Kenvue’s operating environment. The combination of destocking, lower disease incidence, and softer retail dynamics has created a difficult backdrop for achieving growth in the near term.

Within Kenvue’s portfolio, the Skin Health and Beauty segments have emerged as bright spots, showing signs of improvement that analysts characterize as potential indicators of a broader turnaround. These segments represent important growth drivers for the company and could provide momentum if positive trends continue.

The performance in these categories stands in contrast to other parts of the business that continue to face headwinds. Analysts view the strength in Skin Health and Beauty as evidence that certain product lines maintain consumer appeal and pricing power despite broader market challenges. The company’s impressive gross profit margin of 58.6% demonstrates its ability to maintain profitability even during challenging periods, according to InvestingPro data.

The company’s ability to build on this momentum in its stronger segments while addressing weakness elsewhere will be critical to its overall performance trajectory. These product categories typically offer better margins and growth potential compared to more commoditized consumer health products.

Kenvue expects to benefit from foreign exchange tailwinds in the second half of 2025, which should provide some offset to operational challenges. Currency movements have created a more favorable environment for the company’s international operations, particularly as it works to overcome previous headwinds in China.

The China market has been a source of difficulty for Kenvue, but analysts note that the company is making progress in addressing these challenges. As the company moves past these China-related headwinds, the market could contribute more positively to overall results in the latter part of the year and into 2026.

These tailwinds represent important factors in the company’s ability to meet its guidance and potentially set the stage for improved performance. The combination of favorable currency movements and stabilization in key international markets could help offset some of the domestic pressures the company faces.

Kenvue is in the process of searching for a permanent chief executive officer, a transition that analysts view as critical to the company’s long-term direction. The leadership change comes at a pivotal time as the company establishes its identity as an independent entity and works to address operational challenges.

Concurrent with the CEO search, Kenvue is conducting a strategic review to evaluate its business portfolio, operational priorities, and growth strategies. Analysts emphasize that these strategic initiatives may be more important to the company’s future than near-term financial performance, as they will shape the direction of the business for years to come.

The outcome of the strategic review could lead to portfolio adjustments, operational changes, or shifts in capital allocation priorities. Investors are watching these developments closely, as they will provide insight into management’s vision for creating shareholder value and addressing the company’s competitive position.

The timing of these strategic initiatives adds uncertainty to near-term projections, as the new leadership team may implement changes that alter the company’s trajectory. Analysts note that reduced visibility into the timing of any potential turnaround has affected valuation assumptions.

Beyond operational challenges, Kenvue faces litigation risks that add another layer of uncertainty to its outlook. While specific details of the litigation were not provided in available analyst commentary, these legal concerns represent a potential overhang on the stock and could impact financial results depending on outcomes.

Legal issues can create both direct financial costs through settlements or judgments and indirect costs through reputational damage and management distraction. The presence of litigation concerns factors into analyst assessments of risk and valuation for the company.

Analysts project earnings per share of $1.03 for the first fiscal year in their models and $1.08 for the second fiscal year. Looking further ahead, estimates for fiscal year 2027 place earnings per share at $1.23, suggesting gradual improvement in profitability over time as the company works through current challenges. The stock currently trades at a P/E ratio of 20.9 with a notably attractive PEG ratio of 0.39, suggesting the shares may be undervalued relative to growth prospects. Additionally, the company offers a dividend yield of 4.73%, providing income while investors wait for operational improvements. For deeper insights into KVUE’s valuation metrics and growth potential, InvestingPro offers comprehensive analysis including 5 additional exclusive ProTips beyond the ones mentioned here.

These projections incorporate expectations for the company to navigate near-term headwinds while gradually improving operational performance. The modest growth trajectory reflects both the challenges facing the business and the potential for stabilization and recovery in key segments.

The earnings outlook assumes that Kenvue can execute on its strategic initiatives, benefit from improving market conditions in certain categories, and leverage its brand portfolio to drive gradual margin expansion. The path to these earnings levels will depend on successful execution across multiple fronts. Investors seeking a complete picture of KVUE’s investment potential can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities on InvestingPro, which transforms complex Wall Street data into clear, actionable intelligence through intuitive visuals and expert analysis.

The company’s revenue challenges represent a significant concern for investors evaluating the stock’s potential. Destocking pressures have proven persistent, suggesting that retail partners remain cautious about inventory levels amid uncertain consumer demand. This dynamic can create a prolonged period of below-trend growth as the supply chain normalizes.

Low incidence levels for common ailments that drive demand for over-the-counter health products add another dimension to the top-line challenge. If disease incidence remains below historical averages, certain product categories may continue to underperform regardless of the company’s marketing or operational efforts. The company has limited ability to influence these external factors, making revenue growth dependent on variables outside management control.

The combination of destocking and low incidence levels creates a difficult environment for achieving the stabilization needed to meet guidance and return to growth. If these conditions persist longer than anticipated, the company may need to revise expectations downward, potentially disappointing investors who are looking for signs of improvement.

Litigation concerns represent an unknown variable that could materially impact financial results and management focus. Legal proceedings can be unpredictable in both timing and outcome, creating uncertainty around potential financial exposure. Beyond direct costs, litigation can distract management attention from operational priorities and damage brand reputation in ways that affect consumer purchasing decisions.

Slowing retail trends compound these concerns by limiting the company’s ability to offset litigation costs through revenue growth. If retail partners reduce shelf space or promotional support for Kenvue products amid softer traffic trends, the company may struggle to maintain market share. The consumer health products category faces intense competition, and any loss of retail positioning can be difficult to recover.

The convergence of litigation risks and retail headwinds creates a scenario where the company faces multiple challenges simultaneously, limiting its flexibility to address any single issue. This combination of factors could constrain financial performance and strategic options for an extended period.

The positive momentum in Skin Health and Beauty segments provides evidence that Kenvue maintains strong brands with consumer appeal in key categories. These segments typically offer better growth prospects and margins compared to more mature consumer health categories, suggesting that strength here could have an outsized impact on overall financial performance.

If the company can replicate the success seen in Skin Health and Beauty across other parts of its portfolio, the turnaround potential become